Related Experiment Video
Updated: Dec 17, 2025
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
Identification of MicroRNAs With In Vivo Efficacy in Multiple Myeloma-related Xenograft Models
Ulrich H Weidle1, Adam Nopora1
1Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany adam.nopora@roche.com weidle49@t-online.de.
Background/Aim:
Multiple myeloma is a B-cell neoplasm, which can spread within the marrow of the bones forming many small tumors. In advanced disease, multiple myeloma can spread to the blood as plasma cell leukemia. In some cases, a localized tumor known as plasmacytoma is found within a single bone. Despite the approval of several agents such as melphalan, corticosteroids, proteasome inhibitors, thalidomide-based immuno-modulatory agents, histone deacetylase inhibitors, a nuclear export inhibitor and monoclonal antibodies daratuzumab and elatuzumab, the disease presently remains uncurable.
Materials And Methods:
In order to define new targets and treatment modalities we searched the literature for microRNAs, which increase or inhibit in vivo efficacy in multiple-myeloma-related xenograft models.
Results And Conclusion:
We identified six up-regulated and twelve down-regulated miRs, which deserve further preclinical validation.
Insights
Researchers identified specific microRNAs (miRs) that impact multiple myeloma progression in preclinical models. These findings suggest novel therapeutic targets for this incurable B-cell neoplasm.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Multiple myeloma is an incurable B-cell neoplasm affecting bone marrow.
- Advanced disease can manifest as plasma cell leukemia or localized plasmacytoma.
- Current treatments, including novel agents, have not achieved a cure.
Purpose of the Study:
- To identify novel therapeutic targets for multiple myeloma.
- To explore the role of microRNAs in multiple myeloma progression.
- To define microRNAs influencing in vivo efficacy in preclinical models.
Main Methods:
- Literature search for microRNAs (miRs) in multiple myeloma xenograft models.
- Analysis of miRs that increase or inhibit in vivo efficacy.
- Identification of differentially expressed miRs.
Main Results:
- Six up-regulated microRNAs were identified.
- Twelve down-regulated microRNAs were identified.
- These miRs showed an impact on in vivo efficacy in preclinical models.
Conclusions:
- Specific microRNAs warrant further investigation as potential therapeutic targets.
- These findings may lead to new treatment modalities for multiple myeloma.
- Further preclinical validation of identified miRs is recommended.
More Related Videos
05:32Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
Published on: January 7, 2019
10:04Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
